<?xml version="1.0"?>
<Articles JournalTitle="Journal of Pharmaceutical Care">
  <Article>
    <Journal>
      <PublisherName>Tehran University of Medical Sciences</PublisherName>
      <JournalTitle>Journal of Pharmaceutical Care</JournalTitle>
      <Issn>2322-4630</Issn>
      <Volume>10</Volume>
      <Issue>4</Issue>
      <PubDate PubStatus="epublish">
        <Year>2022</Year>
        <Month>12</Month>
        <Day>31</Day>
      </PubDate>
    </Journal>
    <title locale="en_US">Development of Thalassemia Medication Questionnaire (TMQ): An Instrument for Measuring Major Thalassemia Patients&#x2019; Knowledge and Practice Regarding their Medications</title>
    <FirstPage>223</FirstPage>
    <LastPage>228</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName>Azita</FirstName>
        <LastName>Azarkeivan</LastName>
        <affiliation locale="en_US">Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Thalassemia Clinic, Tehran, Iran.</affiliation>
      </Author>
      <Author>
        <FirstName>Ghader</FirstName>
        <LastName>Mohammadnezhad</LastName>
        <affiliation locale="en_US">School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran.</affiliation>
      </Author>
      <Author>
        <FirstName>Hadi</FirstName>
        <LastName>Esmaily</LastName>
        <affiliation locale="en_US">Department of Clinical Pharmacy, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran.</affiliation>
      </Author>
    </AuthorList>
    <History>
      <PubDate PubStatus="received">
        <Year>2022</Year>
        <Month>10</Month>
        <Day>19</Day>
      </PubDate>
      <PubDate PubStatus="accepted">
        <Year>2022</Year>
        <Month>11</Month>
        <Day>23</Day>
      </PubDate>
    </History>
    <abstract locale="en_US">Background: Thalassemia is a congenital disease and Iran is as one of the countries in the thalassemia belt. It has a huge burden in Iranian national health budget. The aim of this study was to develop a questionnaire to assess the knowledge and practice of thalassemia patients toward their medications.
&#xD;

&#xA0;Methods: This is a methodological research, which was done from April 2020 to November 2021 in Tehran, Iran, to develop a valid and reliable instrument for measuring major thalassemia patients&#x2019; knowledge and practice regarding their medications, a questionnaire based on three iron chelating medications (deferoxamine, deferiprone, and deferasirox) developed. This process done by holding several expert panel meetings. This questionnaire was consisting of some aspects such as: administration, self-monitoring, miss dose, common interactions, and adverse events. Content validity index (CVI) and internal consistency and reliability were calculated.&#xA0;
&#xD;

Results: The CVI was as 0.76 for deferoxamine, 0.80 deferiprone and 0.88 for deferasirox questionnaire. Further analysis for internal consistency demonstrated satisfactory results with Cronbach&#x2019;s alpha coefficients ranging from 0.743 to 0.781. Results showed Thalassemia Medication Questionnaire (TMQ) demonstrated acceptable validity and reliability for application.
&#xD;

&#xA0;Conclusion: It was concluded that TMQ could be a useful instrument to measure knowledge and practice about iron chelation therapy. The reason is the diverse range of questions and the simplicity, validity, reliability, and the practicability.</abstract>
    <web_url>https://jpc.tums.ac.ir/index.php/jpc/article/view/541</web_url>
  </Article>
</Articles>
